Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants

Phase 1

Completed

Conditions: Leishmaniasis

Interventions: Drug: GSK3494245
Drug: Placebo

First Posted Date: 2020-08-07

Last Posted Date: 2024-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 59

Registration Number: NCT04504435

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Combination Product: rMenB+OMV NZ vaccine
Combination Product: MenABCWY-1
Combination Product: MenABCWY-3
Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Combination Product: MenABCWY-2
Combination Product: Placebo

First Posted Date: 2020-08-06

Last Posted Date: 2024-03-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3657

Registration Number: NCT04502693

Locations: 🇹🇷
GSK Investigational Site, Kayseri, Turkey

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

Phase 2

Recruiting

Conditions: Arthralgia
Influenza, Human

Interventions: Drug: Zanamivir

First Posted Date: 2020-07-31

Last Posted Date: 2025-03-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT04494412

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Drug-drug Interaction Study of Gepotidacin

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: Gepotidacin
Other: Placebo matching to gepotidacin
Drug: Midazolam
Drug: Cimetidine
Drug: Rifampicin
Drug: Digoxin

First Posted Date: 2020-07-30

Last Posted Date: 2022-03-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 64

Registration Number: NCT04493931

Locations: 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States

Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.

Phase 1

Completed

Conditions: Urinary Tract Infections

Interventions: Drug: GSK3882347
Drug: Placebo

First Posted Date: 2020-07-28

Last Posted Date: 2023-02-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 61

Registration Number: NCT04488770

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2020-07-23

Last Posted Date: 2025-03-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 302

Registration Number: NCT04484623

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Niraparib
Biological: Pembrolizumab
Drug: Placebo

First Posted Date: 2020-07-17

Last Posted Date: 2025-05-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 666

Registration Number: NCT04475939

Locations: 🇬🇧
GSK Investigational Site, Wrexham, United Kingdom

A Clinical Study to Assess Force Required to Dislodge Upper Denture With and Without Use of a Novel Denture Adhesive

Phase 3

Withdrawn

Conditions: Denture Retention

Interventions: Device: Super Poligrip Free
Device: Investigational denture adhesive cream

First Posted Date: 2020-07-16

Last Posted Date: 2021-01-22

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT04473521

Locations: 🇺🇸
Indiana University School of Dentistry, Indianapolis, Indiana, United States

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants

Phase 1

Terminated

Conditions: Tuberculosis

Interventions: Drug: Placebo
Drug: GSK2556286

First Posted Date: 2020-07-16

Last Posted Date: 2025-05-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 92

Registration Number: NCT04472897

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Drug: GSK3228836
Drug: Placebo
Drug: Nucleos(t)ide therapy

First Posted Date: 2020-06-26

Last Posted Date: 2023-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 457

Registration Number: NCT04449029

Locations: 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy